Association of circulating tumor cells (CTCs) with immune checkpoint inhibitor (ICI) responses in metastatic renal cell carcinoma (mRCC)

被引：0

作者：

Zhang, T. ^{[1
]}

Poellmann, M. ^{[2
]}

Park, S-J. ^{[2
]}

Bu, J. ^{[2
]}

Zhao, R. ^{[1
]}

Zhou, Q. ^{[1
]}

Agarwal, A. ^{[3
]}

Parks, J. ^{[4
]}

Reyes-Martinez, M. ^{[4
]}

Armstrong, A. J. ^{[5
]}

George, D. J. ^{[4
]}

Wang, A. Z. ^{[6
]}

Hong, S. ^{[2
]}

机构：

[1] UTSW Univ Texas Southwestern Med Ctr, Internal Med, Dallas, TX USA

[2] Univ Wisconsin, Pharmaceut Sci, Madison, WI USA

[3] Univ North Carolina Chapel Hill, Sch Med, Chapel Hill, NC USA

[4] Duke Univ Med Ctr, Duke Canc Ctr, Med, Durham, NC USA

[5] Duke Canc Ctr, Med, Durham, NC USA

[6] UTSW Univ Texas Southwestern Med Ctr, Radiat Oncol, Dallas, TX USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.1578

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1475P

引用

页码：S1221 / S1221

页数：1

共 50 条

[21] A MULTICENTER ASSESSMENT OF SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) WHO RECEIVED IMMUNE CHECKPOINT INHIBITOR THERAPY (ICI) WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY (CN)
Gross, Evan
Li, Mingjia
Yin, Ming
Orcutt, Delaney
Hussey, Duncan
Trott, Elliot
Kramer, Joel
Oliva, Kaylee
Gore, John
Schade, George
Lin, Daniel
Tykodi, Scott
Hall, Evan
Thompson, John
Parikh, Anish
Yang, Yuanquan
Collier, Katharine
Miah, Abdul
Mori-Vogt, Sherry
Hinkley, Megan
Mortazavi, Amir
Monk, Paul
Folefac, Edmund
Clinton, Steven
Psutka, Sarah
JOURNAL OF UROLOGY, 2021, 206 : E255 - E255
[22] Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC)-an International mRCC Database Consortium (IMDC) analysis
Araujo, Daniel, V
Wells, J. Connor
Hansen, Aaron R.
Dizman, Nazli
Pal, Sumanta K.
Beuselinck, Benoit
Donskov, Frede
Gan, Chun L.
Yan, Flora
Tran, Ben
Kollmannsberger, Christian K.
de Velasco, Guillermo
Yuasa, Takeshi
Reaume, M. Neil
Ernst, D. Scott
Powles, Thomas
Bjarnason, Georg A.
Choueiri, Toni K.
Heng, Daniel Y. C.
Dudani, Shaan
JOURNAL OF GERIATRIC ONCOLOGY, 2021, 12 (05) : 820 - 826
[23] Elevated serum DC-HIL is associated with poor response to immune checkpoint inhibitors (ICI) in metastatic renal cell carcinoma (mRCC)
Chung, Jin-Sung
Ramani, Vijay
Cruz, Ponciano D.
Hammers, Hans J.
Ariizumi, Kiyoshi
CANCER RESEARCH, 2022, 82 (12)
[24] Baseline modified Glasgow prognostic score (mGPS) in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI).
Brown, Jacqueline T.
Liu, Yuan
Martini, Dylan J.
Shabto, Julie M.
Russler, Greta
Caulfield, Sarah
Yantorni, Lauren Beth
Joshi, Shreyas S.
Kissick, Haydn
Ogan, Kenneth
Nazha, Bassel
Carthon, Bradley Curtis
Kucuk, Omer
Harris, Wayne
Master, Viraj A.
Bilen, Mehmet Asim
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[25] Circulating tumor cells status in metastatic renal cell carcinoma (mRCC) after metastasectomy (RESORT trial)
Verzoni, E.
Grassi, P.
Cappelleti, V.
Maggi, C.
Montone, R.
de Braud, F.
Procopio, G.
ANNALS OF ONCOLOGY, 2015, 26 : 63 - 63
[26] Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma
Brown, Landon C.
Zhu, Jason
Desai, Kunal
Kinsey, Emily
Kao, Chester
Lee, Yong Hee
Pabla, Sarabjot
Labriola, Matthew K.
Tran, Jennifer
Dragnev, Konstantin H.
Tafe, Laura J.
Dayyani, Farshid
Gupta, Rajan T.
McCall, Shannon
George, Daniel J.
Glenn, Sean T.
Nesline, Mary K.
George, Saby
Zibelman, Matthew
Morrison, Carl
Ornstein, Moshe C.
Zhang, Tian
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (10)
[27] Impact of CBM588 on gut microbiome composition and dysbiosis in patients receiving frontline immune checkpoint inhibitor (ICI) combinations for metastatic renal cell carcinoma (mRCC)
Dizman, Nazli
Ebrahimi, Hedyeh
Barragan-Carrillo, Regina
Meza, Luis A.
Bergerot, Paulo
Dorff, Tanya
Hsu, JoAnn
Zengin, Zeynep
Castro, Daniela
Chehrazi-Raffle, Alex
Triphathi, Abhishek
Trent, Jeffrey
Takahashi, Motomichi
Oka, Kentaro
Higashi, Seiya
Caporaso, Gregory
Lee, Keehoon
Pal, Sumanta K.
ONCOLOGIST, 2024, 29 : S6 - S6
[28] Impact of CBM588 on gut microbiome composition and dysbiosis in patients receiving frontline immune checkpoint inhibitor (ICI) combinations for metastatic renal cell carcinoma (mRCC)
Dizman, Nazli
Ebrahimi, Hedyeh
Carrillo, Regina Barragan
Meza, Luis A.
Bergerot, Paulo Gustavo
Dorff, Tanya B.
Hsu, Joann
Zengin, Zeynep Busra
Castro, Daniela V.
Chehrazi-Raffle, Alex
Tripathi, Abhishek
Trent, Jeffrey M.
Takahashi, Motomichi
Oka, Kentaro
Higashi, Seiya
Caporaso, Gregory
Lee, Keehoon
Pal, Sumanta Kumar
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[29] SALVAGE IMMUNE CHECKPOINT INHIBITOR (IO) PLUS TYROSINE KINASE INHIBITOR (TKI) COMBINATION THERAPY FOR METASTATIC RENAL CELL CARCINOMA (MRCC)
Parikh, Anish
Psutka, Sarah
Yang, Yuanquan
Collier, Katharine
Miah, Abdul
Li, Mingjia
Mori-Vogt, Sherry
Hinkley, Megan
Mortazavi, Amir
Monk, Paul
Folefac, Edmund
Clinton, Steven
Orcutt, Delaney
Gross, Evan
Hussey, Duncan
Trott, Elliot
Kramer, Joel
Oliva, Kaylee
Gore, John
Schade, George
Lin, Daniel
Tykodi, Scott
Hall, Evan
Thompson, John
Yin, Ming
JOURNAL OF UROLOGY, 2021, 206 : E261 - E261
[30] Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC): An international mRCC database consortium (IMDC) analysis.
Araujo, Daniel Vilarim
Wells, Connor
Hansen, Aaron Richard
Dizman, Nazli
Pal, Sumanta K.
Beuselinck, Benoit
Donskov, Frede
Gan, Chun Loo
Yan, Flora
Tran, Ben
Kollmannsberger, Christian K.
de Velasco, Guillermo
Yuasa, Takeshi
Reaume, M. Neil
Ernst, D. Scott
Powles, Thomas
Bjarnason, Georg A.
Choueiri, Toni K.
Heng, Daniel Yick Chin
Dudani, Shaan
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →